Thiazolides: A new class of antiviral drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 6, 2009, Pages 667-674

  Rossignol, Jean François ^a  

^a Romark Institute for Medical Research   (United States)

Author keywords

Antiviral; Hepatitis B; Hepatitis C; Nitazoxanide; Rotavirus; Thiazolides

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; INTERFERON; LAMIVUDINE; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; RM 4850; RM 4865; RM 5036; RM 5037; THIAZOLIDE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG; VIRUS RNA; WARFARIN;

ABDOMINAL PAIN; ADD ON THERAPY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CARCINOGENICITY; CARDIOTOXICITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; EMBRYOTOXICITY; GIARDIA LAMBLIA; HEADACHE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYMENOLEPIS NANA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PARASITOSIS; PROTOZOON; QT PROLONGATION; REPLICON; REVIEW; ROTAVIRUS; STRUCTURE ACTIVITY RELATION; TAENIA SAGINATA; TERATOGENICITY; TREATMENT PLANNING; VIRAL GASTROENTERITIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GASTROENTERITIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; THIAZOLES;

HEPATITIS C VIRUS; ROTAVIRUS;

EID: 67649307146     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902988487     Document Type: Review

References (50)

1. Rossignol JF, Cavier R. 2-benzamido 5-nitrothiazoles. Chem Abstr 1975;84:28216n
2. Rossignol JF, Maisonneuve H, Cho YW. Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int J Clin Pharmacol Ther Toxicol 1984;22:63-72
3. Liu LX, Weller PF. Antiparasitic drugs. N Engl J Med 1996;334:1178-1184
4. Katz M. Anthelmintics. Current concepts in the treatment of helminthic infections. Drugs 1986;32:358-371
5. Zhong HL, Cao WJ, Rossignol JF, et al. Albendazole in nematode, cestode, trematode and protozoan (Giardia) infections. Chin Med J 1986;11:912-915 (Pubitemid 17226488)
6. Euzéby J, Prom Tep S, Rossignol JF. Expérimentation des propriétés anthelminthiques de la nitazoxanide chez le chien, le chat et les ovins. Revue de Médecine Vétérinaire 1980;131:687-696 (Pubitemid 11161770)
7. Cavier R, Rossignol JF. Etude pharmacologique de diverses associations d'anthelminthiques chez la souris. Revue de Médecine Vété rinaire 1982;133:779-783 (Pubitemid 13195827)
8. Rossignol JF, Cavier R. New derivatives of 2-benzamido 5-nitrothiazoles. US Patent 3950351; 1976
9. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana. Am J Trop Med Hyg 1984;33:511-512 (Pubitemid 14075656)
10. Rossignol JF, Maisonneuve H. Albendazole: a new concept in the treatment of intestinal helminthiasis. Gastroentérol Clin. Biol 1984;8:569-576 (Pubitemid 14083569)
11. Fox L, Saravolatz LD. Nitazoxanide a new thiazolide antiparasitic agent. Clin Infect Dis 2006;40:1173-1180
12. Romark Laboratories. Alinia® (nitazoxanide) prescribing information. June, 2005
13. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of hepatitis B and C. Future Microbiol 2008;3:539-545
14. Korba BE, Mueller AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res 2008;77:56-63
15. Rossignol JF, Abou-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide in treating severe rotavirus diarrhea: a randomized, double-blind, placebo-controlled trial. Lancet 2006;368:124-129 (Pubitemid 43994153)
16. Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double blind placebo controlled trial. Aliment Pharmacol Ther 2006;24:1423-1430 (Pubitemid 44657118)
17. Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis In press
18. Hoffman PS, Sisson G, Croxen MA, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductasess of Helicobacter pylori, selected anaerobic bacteria and parasites and Campilobacter jejuni. Antimicrob Agents Chemother 2007;51:868-876 (Pubitemid 46355269)
19. Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002;511:133-144
20. Santoro MG, Ciucci A, Gianferritti P, et al. Thiazolides: a new class of broad-spectrum antiviral drugs targeting virus maturation. Antivir Res 2007;74:A31
21. Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J Biol Chem. In press
22. Stockis A, De Bruyn S, Gengler C, Rosillon D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int J Clin Pharmacol Ther 2002;40:221-227 (Pubitemid 34467681)
23. Adagu IS, Nolder D, Warhurst D, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 2002;49:103-111
24. Pankuch GA, Appelbaum PC. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic bacteria. Antimicrob Agents Chemother 2006;50:112-117 (Pubitemid 43327824)
25. Müller J, Rühle G, Müller N, et al. In vitro effects of thiazolides on Giardia lamblia WB C6 cultured axenically and in co-culture with Caco2 cells. Antimicrob Agents Chemother 2006;50:162-170
26. Korba BE, Elazar M, Lui P, et al. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology 2008;48(Suppl):356A
27. Korba BE, Elazar M, Lui P, et al. Studies of the potential for nitazoxanide or tizoxanide resistance in hepatitis C virus replicon-containing cell lines. Antimicrob Agents Chemother 2008;52:4069-4071
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25 (Pubitemid 27046991)
29. Broekhuysen J, Stockis A, Lins RL, et al. Nitazoxanide: Pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000;38:387-394 (Pubitemid 30650157)
30. Stockis A, Allemon AM, De Bruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int J Clin Pharmacol Ther 2002;40:213-220 (Pubitemid 34467680)
31. Vets E, Rossignol JF, Jackson AS. Effect of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Am J Health Syst Pharm. 2009;66:838-842
32. Rossignol JF, Kabil SM, El-Gohary YM, et al. Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008;28:574-580
33. Rossignol JF, Elfert A, El-Gohary Y, Keefe EB. Improved virologic response in chronic hepatitis C genotype 4 patients treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-862
34. Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol Ther 2006;24:887-894 (Pubitemid 44244913)
35. Bacon BR, Shiffman ML, Lim JK, Berman A, Rustgi VK, Keeffe EB; STEALTH C-3 Investigators. Phase II randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in hepatitis C genotype 1 naïve patients: interim analysis shows increase in EVR. J Hepatol In press
36. Shiffman ML, Ahmed A, Jacobson IM, Pruitt RE, Keeffe EB; STEALTH C-2 Investigators. Phase II randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis. J Hepatol In press
37. Keeffe EB, Rossignol JF, Elfert A, et al. Controlled release tablet improves pharmacokinetics, viral kinetics and tolerability of nitazoxanide for treatment of chronic hepatitis C. Hepatol Int. 2009;3:49
38. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report. Hepatology 2008;48:344A-5A
39. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a propective randomized double-blind placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:103-106 (Pubitemid 32568508)
40. Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002;360:1375-1380 (Pubitemid 35341302)
41. Rossignol JF, Kabil SM, Younis AM, El-Gohary Y. Double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in 90 immunocompetent adults and adolescents from the Nile delta of Egypt. Clin Gastroenterol Hepatol 2006;4:320-324
42. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica/ dispar: a double blind placebo controlled study of nitazoxanide. J Infect Dis 2001;184:381-384 (Pubitemid 32662190)
43. Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15:1409-1415 (Pubitemid 32835549)
44. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amebiasis. Trans R Soc Trop Med Hyg 2007;101:1025-1031
45. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide in the treatment of Clostridium difficile associated diseases. Clin Infect Dis 2006;43:421-427 (Pubitemid 44157148)
46. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-6
47. Abubakar I, Aliyu SG, Arumugam C, et al. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol 2007;63:387-393 (Pubitemid 46426641)
48. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and ef?cacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-477 (Pubitemid 27328328)
49. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitits C: results of a placebo-controlled study. J Hepatol 1996;25:591-598 (Pubitemid 26373872)
50. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 2006;101:842-847